Stock Research for PCRX


Featured Broker: Ally Invest

Get the due diligence for another stock.


PCRX Stock Chart & Research Data

The PCRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PCRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PCRX Due diligence Resources & Stock Charts

The PCRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PCRX Detailed Price Forecast - CNN Money CNN View PCRX Detailed Summary - Google Finance
Yahoo View PCRX Detailed Summary - Yahoo! Finance Zacks View PCRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View PCRX Trends & Analysis - Trade-Ideas Barrons View PCRX Major Holders - Barrons
NASDAQ View PCRX Call Transcripts - NASDAQ Seeking View PCRX Breaking News & Analysis - Seeking Alpha
Spotlight View PCRX Annual Report - OTC Report View PCRX OTC Short Report -
TradeKing View PCRX Fundamentals - TradeKing Charts View PCRX SEC Filings - Bar Chart
WSJ View Historical Prices for PCRX - The WSJ Morningstar View Performance/Total Return for PCRX - Morningstar
MarketWatch View the Analyst Estimates for PCRX - MarketWatch CNBC View the Earnings History for PCRX - CNBC
StockMarketWatch View the PCRX Earnings - StockMarketWatch MacroAxis View PCRX Buy or Sell Recommendations - MacroAxis
Bullish View the PCRX Bullish Patterns - American Bulls Short Pains View PCRX Short Pain Metrics -

Social Media Mentions

StockTwits View PCRX Stock Mentions - StockTwits PennyStocks View PCRX Stock Mentions - PennyStockTweets
Twitter View PCRX Stock Mentions - Twitter Invest Hub View PCRX Investment Forum News - Investor Hub
Yahoo View PCRX Stock Mentions - Yahoo! Message Board Seeking Alpha View PCRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PCRX - Insider Cow View Insider Transactions for PCRX - Insider Cow
CNBC View PCRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PCRX - OTC Markets
Yahoo View Insider Transactions for PCRX - Yahoo! Finance NASDAQ View Institutional Holdings for PCRX - NASDAQ

Stock Charts

FinViz View PCRX Stock Insight & Charts - StockCharts View PCRX Investment Charts -
BarChart View PCRX Stock Overview & Charts - BarChart Trading View View PCRX User Generated Charts - Trading View

Latest Financial News for PCRX

Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment
Posted on Friday June 22, 2018

Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.

Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China
Posted on Tuesday June 19, 2018

Pacira Pharmaceuticals, Inc. (PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.

Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown-Forman, Pacira Pharmaceuticals, Team, and Solaris Oilfield Infrastructure — Fundamental Analysis, Key Performance Indications
Posted on Monday June 18, 2018

NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip ...

Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL®
Posted on Friday June 15, 2018

Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (bupivacaine liposome injectable suspension), to manage postsurgical pain. This initiative builds off a national program launched by Pacira, Aetna, and the American Association of Oral and Maxillofacial Surgeons (AAOMS) in September 2017 aimed at reducing the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.

Enter a stock symbol to view the stock details.